行情

ACOR

ACOR

阿索尔达治疗
NASDAQ

实时行情|Nasdaq Last Sale

1.040
-0.070
-6.31%
盘后: 1.060 +0.02 +1.92% 16:46 03/27 EDT
开盘
1.090
昨收
1.110
最高
1.170
最低
1.040
成交量
90.38万
成交额
--
52周最高
13.53
52周最低
0.7001
市值
4,991.69万
市盈率(TTM)
-0.1809
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测ACOR价格均价为3.917,最高价位10.00,最低价为1.000。

EPS

ACOR 新闻

更多
  • The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates
  • Benzinga · 03/18 11:36
  • What Makes Acorda (ACOR) a New Buy Stock
  • Zacks · 03/17 17:00
  • Why Is Acorda (ACOR) Down 54.7% Since Last Earnings Report?
  • Zacks · 03/14 16:30
  • The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
  • Benzinga · 03/12 11:37

所属板块

生物技术和医学研究
-2.43%
制药与医学研究
-0.87%

热门股票

代码
价格
涨跌幅

ACOR 简况

Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS). The Company also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company has a pipeline of neurological therapies addressing a range of disorders, including Parkinson's disease, migraine and MS. The Company's product candidate, CVT-301, is a self-administered inhaled formulation of levodopa.
展开

微牛提供Acorda Therapeutics Inc(NASDAQ-ACOR)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的ACOR股票新闻,以帮助您做出投资决策。